The story of Sildenafil presents a complex case for stakeholders in the pharmaceutical sector. While initially a blockbuster success, generating huge profits, the exclusivity end and the subsequent arrival of cheaper alternatives have drastically impacted revenue. This presents questions about the future profitability of analogous medication dev… Read More